Fulcrum Therapeutics, INC

Fulcrum Therapeutics and Slate Medicines have agreed to a merger, combining forces to advance Slate's migraine therapeutics pipeline, supported by a $245 million financing round.

Fulcrum Therapeutics announced the appointment of Alan Musso as Principal Accounting Officer, effective August 7, 2026, following the departure of Greg Tourangeau.

Fulcrum Therapeutics stockholders elected three directors, approved executive compensation, and ratified auditors.

Fulcrum Therapeutics implements a restructuring plan, including executive retention bonuses and the departure of its principal accounting officer.

Fulcrum Therapeutics announces a significant restructuring, including an 85% workforce reduction and discontinuation of a sickle cell disease drug, while simultaneously initiating a comprehensive review of strategic alternatives.

Fulcrum Therapeutics announced the termination of its license agreement with CAMP4 Therapeutics, the appointment of Josh Lehrer to its Board of Directors, and reported Q1 2026 financial results, including positive clinical data for pociredir.

Fulcrum Therapeutics details first-quarter 2026 financial results, highlighting progress in its lead drug candidate pociredir for Sickle Cell Disease and continued focus on rare disease therapies.

Fulcrum Therapeutics reported a net loss of $19.6 million for Q3 2025, driven by R&D focus on pociredir for sickle cell disease, which showed promising Phase 1b results, while the losmapimod program was terminated.

Fulcrum Therapeutics experienced significant net losses in Q2 2025 following the termination of its Sanofi collaboration and discontinuation of the Losmapimod program, while reporting promising Phase 1b clinical data for its lead sickle cell disease candidate, Pociredir.

Fulcrum Therapeutics reports a net loss of $17.7 million for Q1 2025, focusing on pociredir development and inherited aplastic anemia programs.

Fulcrum Therapeutics reported a net income of $6.8 million for the nine months ended September 30, 2024, primarily due to a collaboration agreement, and announced a strategic shift in research and development focus.

Fulcrum Therapeutics has entered into a significant collaboration and license agreement with Sanofi, granting exclusive rights to commercialize losmapimod, a potential treatment for facioscapulohumeral muscular dystrophy (FSHD), outside the United States.

Fulcrum Therapeutics' 2025 annual report highlights promising Phase 1b pociredir data for sickle cell disease and a strengthened financial position, despite a significant net loss.

Fulcrum Therapeutics announces its 2024 financial results and a strategic realignment focusing on pociredir for sickle cell disease and novel therapies for inherited aplastic anemias after suspending losmapimod development.

Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, reported its 2023 financial results and operational progress, highlighting advancements in its lead programs, losmapimod for FSHD and pociredir for SCD.

Fulcrum Therapeutics and Slate Medicines announce a definitive agreement to combine in an all-stock transaction, creating Slate Medicines, Inc. with a $245 million private placement.

Fulcrum Therapeutics and Slate Medicines are merging in an all-stock transaction, aiming to create a well-capitalized migraine-focused biotech company with a projected cash runway into 2029.

Fulcrum Therapeutics and Slate Medicines announce a merger agreement, combining forces to advance Slate's migraine therapeutics pipeline, supported by a $245 million financing.

Kevin Tang and 1 other reported changes in beneficial ownership of Fulcrum Therapeutics, Inc. common stock on July 16, 2026.

Kevin Tang and 1 other reported changes in beneficial ownership of Fulcrum Therapeutics, Inc. common stock on July 13, 2026.

Fulcrum Therapeutics Director Katina Dorton acquired 32,000 stock options with an exercise price of $3.66, vesting on June 30, 2026.

Fulcrum Therapeutics files an amendment to its definitive proxy statement to include the sample proxy card for the 2025 Annual Meeting of Stockholders.

Fulcrum Therapeutics will hold its annual stockholders meeting on June 26, 2025, to elect directors, vote on executive compensation, and ratify the appointment of Ernst & Young LLP as its independent accounting firm.

Fulcrum Therapeutics announces its 2025 annual meeting of stockholders to be held virtually on June 26, 2025, covering director elections, executive compensation, and auditor ratification.

Fulcrum Therapeutics will hold its annual stockholders meeting virtually on June 17, 2024, to elect directors and ratify the appointment of Ernst & Young LLP as its independent accounting firm.

Fulcrum Therapeutics will hold its 2024 annual meeting of stockholders virtually on June 17, 2024, to vote on director elections and the ratification of its independent accounting firm.

RA Capital Management, L.P. and related entities have filed an amendment to their Schedule 13G, reporting zero beneficial ownership of Fulcrum Therapeutics, Inc. common stock as of June 30, 2026.

Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, has reported beneficial ownership of 5,475,040 shares, representing 8.22% of Fulcrum Therapeutics, Inc.'s common stock as of June 30, 2026.

Montanova Capital, Averill Master Fund, and Aaron Cowen have collectively increased their beneficial ownership in Fulcrum Therapeutics to 5.5% and 3.8% respectively, as of June 30, 2026.

TCG Crossover Fund II, L.P. and TCG Crossover GP II, LLC, along with Chen Yu, have filed an amendment to their Schedule 13G for Fulcrum Therapeutics, Inc., reporting no change in beneficial ownership.

Bank of America Corp /DE/ has reported beneficial ownership of 4,468,123 shares, representing 6.7% of the common stock of Fulcrum Therapeutics, Inc.

Tang Capital Management and affiliated entities have reported beneficial ownership of 10.4% of Fulcrum Therapeutics, Inc. common stock.